# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

A. 510(k) Number: k090563   
B. Purpose for Submission: To seek clearance for the following devices: 1. Tri-level quality control plasmas 2. Four-level calibration plasmas 3. ISIweb software   
C. Measurand: Prothrombin Time (PT), INR (International Normalized Ratio), ISI (International Sensitivity Index), and Mean Normal Prothrombin Time (MNPT)   
D. Type of Test: Control and Calibrator plasmas: clotting assay. ISIweb: calculator/data processing module for clinical use.   
E. Applicant: Instrumentation Laboratory Co.   
F. Proprietary and Established Names: HemosIL® INR Validate HemosIL® ISI Calibrate ISIweb Software   
G. Regulatory Information: 1. Regulation section: 21 CFR 864.5425; Multipurpose system for in vitro coagulation studies 21 CFR 862.1150; Calibrator 21 CFR 862.2100; Calculator/data processing module for clinical use 2. Classification: Class II: (Controls and Calibrators) Class I: (ISIweb) 3. Product code: GGN; Plasma, Coagulation Control JIS; Calibrator, primary JQP Calculator/Data Processing Module, For Clinical Use 4. Panel: Hematology (81)   
H. Intended Use:

1. Intended use(s): HemosIL INR Validate is a tri-level quality control intended to monitor the accuracy of INR (International Normalized Ratio) reporting with designated HemosIL PT reagents on IL Coagulation Systems in conjunction with the ISIweb software.

HemosIL ISI Calibrate is a set of four certified plasma intended to establish a laboratory’s instrument/reagent specific local ISI (International Sensitivity Index) and Mean Normal Prothrombin Time (MNPT) with designated HemosIL PT reagents on IL Coagulation Systems in conjunction with the ISIweb software.

ISIweb Software is a web-based service to customers, used in conjunction with HemosIL INR Validate and HemosIL ISI Calibrate with designated HemosIL PT reagents on IL Coagulation Systems, whereby the PT seconds and INR results can be entered and calculated through a web-based interface (ISIweb software).

2. Indication(s) for use: Same as Intended Use   
3. Special conditions for use statement(s): Prescription Use only   
4. Special instrument requirements: IL Coagulation Systems: ACL TOP Family, ACL Futura Advance, ACL 8/9/10000/Elite/Pro, ACL 100 - 7000

# I. Device Description:

1. HemosIL® INR Validate: the control set consists of three-levels of lyophilized citrated control plasmas which have assigned INR reference values in the range of 1.6 - 5.0. Level 1 has an INR range of 1.6 - 2.4, Level 2 of 2.5 - 3.5, and Level 3 of 3.8 - 5.0. The reference INR values for each level are reagent-specific for the IL coagulation systems. The plasmas are collected from human donors on stable antivitamin K therapy. The INRs are monitored by running the controls on a local instrument/reagent system using the laboratory’s locally established lot-specific MNPT and manufacturer’s lot-specific ISI value.

2. HemosIL® ISI Calibrate: The calibrator set contains four-levels of lyophilized citrated calibration plasmas which have assigned INR reference values in the range of 0.9 – 5.0. Level A has an INR range of 0.9 – 1.1, Level B of 1.6 – 2.4, Level C of 2.5 – 3.5, and Level D of 3.8 – 5.0. The reference INR values for each level are reagent-specific for the $\mathrm { I L }$ coagulation systems. Level A is collected from normal human pool. Levels B, C, and D are collected from a pool of human donors on stable anti-vitamin K therapy.

3. ISIweb: ISIweb is a web-based service for customers used in conjunction with designated HemosIL PT reagents on IL coagulation systems, whereby the PT and INR results can be entered and calculated.

# J. Substantial Equivalence Information:

1. Predicate device name(s): Pacific Hemostasis INR Control Plasma HemosIL Calibration Plasma   
2. Predicate K number(s): k010750 k041905   
3. Comparison with predicate:

HemosIL® INR Validate  

<table><tr><td colspan="3">Similarities</td></tr><tr><td>Item</td><td>Device</td><td>Predicate</td></tr><tr><td>Indications for Use</td><td>HemosIL INR Validate is a tri- level quality control intended to monitor the accuracy of INR reporting with designated HemosIL PT reagents on IL</td><td>Pacific Hemostasis INR controls, levels 1-5, are intended for use as controls to check the performance of PT testing. Pacific Hemostasis warrants the INR values of control</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Coagulation systems.</td><td colspan="1" rowspan="1">plasma only for use with PacificHemostasis brandThromboPlastTins.</td></tr><tr><td colspan="1" rowspan="1">Instrument/ReagentTest System</td><td colspan="1" rowspan="1">PT reagent-specific INR referencevalues for IL Coagulation Systems</td><td colspan="1" rowspan="1">Instrument/Reagent specific INRreference values</td></tr></table>

HemosIL® ISI Calibrate  

<table><tr><td rowspan=1 colspan=1>Jllt7 1t0asTest System</td><td rowspan=1 colspan=1>values for IL Coagulation Systems</td><td rowspan=1 colspan=1>reference values</td></tr><tr><td></td><td></td><td></td></tr><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Certification</td><td rowspan=1 colspan=1>The three control plasmas arecertified, with INR referencevalues traceable to WHOInternational ReferenceThromboplastins and consensustesting from &gt;200 laboratories.</td><td rowspan=1 colspan=1>The reference values arecalculated by the manufacturerfrom the mean normal PT (MNPT)for each reagent/instrumentcombination of ≥ 20 and thethromboplastin ISI, which isdirectly traceable to the WHOInternational ReferenceThromboplastins.</td></tr><tr><td rowspan=1 colspan=1>INR Levels</td><td rowspan=1 colspan=1>Level 1: 1.6-2.4Level 2: 2.5 -3.5Level 3: 3.8 -5.0</td><td rowspan=1 colspan=1>Level 1: 1 -1.4Level 2: 1.5 -2.0Level 3: 2.1 -2.7Level 4: 2.8 -3.5Level 5: 3.6-5</td></tr><tr><td rowspan=1 colspan=1>Preparation</td><td rowspan=1 colspan=1>Prepared using lyophilized citratedplasma from human donors onstable anti-vitamin K therapy(AVK), in which the plasmafactors are similar to those levelsnormally expected in plasma frompatients undergoing long-term oralanticoagulant therapy, togetherwith the proteins induced byvitamin K antagonists.</td><td rowspan=1 colspan=1>Prepared using lyophilized citratedplasma from healthy donors. Theplasma are adjusted during themanufacturing proves to yield theclot times with an INR rangesfrom 1 to 5.2.</td></tr><tr><td rowspan=1 colspan=1>Composition</td><td rowspan=1 colspan=1>Lyophilized human plasma withbuffer, no preservative.</td><td rowspan=1 colspan=1>Lyophilized human plasma withbuffer and stabilizer.</td></tr></table>

<table><tr><td colspan="3">Similarities</td></tr><tr><td>Item</td><td>Device</td><td>Predicate</td></tr><tr><td>Indications for Use</td><td>HemosIL ISI Calibrate is a set of four certified plasmas intended to establish a laboratory's instrument/reagent specific local ISI (International Sensitivity</td><td>Calibration of coagulation assays on both ELECTRA and IL Coagulation systems</td></tr><tr><td></td><td>Index) and Mean Normal Prothrombin Time (MNPT) with designated HemosIL PT reagents on IL Coagulation Systems in conjunction with the ISIweb software.</td><td></td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Indications for Use</td><td rowspan=1 colspan=1>HemosIL ISI Calibrate is a set offour certified plasmas intended toestablish a laboratory&#x27;sinstrument/reagent specific localISI (International SensitivityIndex) and Mean NormalProthrombin Time (MNPT) withdesignated HemosIL PT reagentson IL Coagulation Systems inconjunction with the ISIwebsoftware.</td><td rowspan=1 colspan=1>Calibration of coagulation assayson both ELECTRA and ILCoagulation systems</td></tr><tr><td rowspan=1 colspan=1>Certification</td><td rowspan=1 colspan=1>The four calibrate plasmas arecertified, with INR referencevalues traceable to WHOInternational referencethromboplastins and consensustesting from &gt;200 laboratories.ISI values in the consensus testingcome from label values traceableto the WHO laboratories.</td><td rowspan=1 colspan=1>Recommendation to useinternational referencethromboplastin (IRP) using themanual tilt-tube technique from atleast two different WHO centerswith locally determined MNPT.</td></tr><tr><td rowspan=1 colspan=1>INR Levels</td><td rowspan=1 colspan=1>Level A: 0.9 - 1.1Level B: 1.6 - 2.4Level C: 2.5 - 3.5Level D: 3.8 - 5.0</td><td rowspan=1 colspan=1>Calibrate using control plasmas</td></tr><tr><td rowspan=1 colspan=1>Preparation</td><td rowspan=1 colspan=1>Prepared using lyophilized citratedplasmas. Normal (Level A) fromnormal human pool. Levels B, C,and D from human donors onstable anti-vitamin K therapy. Nopreservative.</td><td rowspan=1 colspan=1>Lyophilized citrated plasmacontaining buffer andpreservatives. The calibrationplasma is prepared using citratedplasma from healthy donors bymeans of a dedicated process tomaintain the characteristics of anormal plasma pool.</td></tr><tr><td rowspan=1 colspan=1>Composition</td><td rowspan=1 colspan=1>Lyophilized human plasma withbuffer.</td><td rowspan=1 colspan=1>Lyophilized plasma with minimaladditives recommended foradequate stability.</td></tr></table>

K. Standard/Guidance Document Referenced: CLSI EP05-A2: Evaluation of Precision Performance of Quantitative Measurement

Methods; Approved Guideline, $2 ^ { \mathrm { n d } }$ Ed.

CLSI H54-A: Procedure for validation of INR and Local Calibration of PT/INR Systems; Approved Guideline.

# L. Test Principle:

HemosIL® INR Validate:

As determined through the ISIweb software, the PT/INR system is verified if the mean INRs of all controls are within $0 f \pm 1 5 \%$ of their assigned INR reference values. If the mean INRs of all the controls are within $\pm 1 5 \%$ of their assigned INR reference values, the PT/INR system is verified. If the mean INRs of the controls are not within $\pm 1 5 \%$ of their assigned INR reference values, a new local ISI calibration is recommended using the HemosIL ISI calibrate set. The new local ISI and MNPT is verified by re-running the HemosIL INR Validate controls on the same instrument/reagent system with the local ISI and MNPT

# $\mathbf { H e m o s I L } ^ { \mathbf { \otimes } }$ ISI Calibrate:

To establish a local ISI, the calibrate plasmas are run on the IL instrument/reagent system. The PT (second) data is entered into the ISIweb, which will generate a calibration curve from the PT and the INR reference values by plotting an orthogonal regression of LogINR (x-axis) vs. LogPT (y-axis). From the slope and y-intercept of the curve, the ISI and MNPT are derived as follows:

# ISIweb:

When used in conjunction with HemosIL Validate, the mean INR for each control level will be automatically calculated by ISIweb. The ISIweb will verify whether the mean INR for each level of control is within $\pm 1 5 \%$ of the assigned INR reference values. When used in conjunction with HemosIL ISI Calibrate, the mean PT and $\%$ CV value of each calibrator level is automatically calculated by the ISIweb software. For each level of the calibrator, if the $\%$ CV passes specification, ISIweb generates a calibration curve from the PT and INR reference values by plotting an orthogonal regression of LogINR (x-axis) vs. LogPT (y-axis).

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

The precision study was performed in accordance with CLSI EP05-A2, Evaluation of Precision Performance of Quantitative Measurement Methods, on one lot. Two replicates per run, two runs per day, 20 days $( \mathrm { n } { = } 8 0 )$ ) per level on three levels of Validate and four levels of Calibrate using HemosIL reagents on representative IL instruments: ACL TOP and ACL 10000. For the HemosIL Validate, levels 1-3 met their within-run $\%$ CV specification of $6 \%$ . For the HemosIL Calibrate, Level A and Levels B-D met their within-run $\% \mathrm { C V }$ specification of $\leq 3 \%$ and $\leq 6 \%$ , respectively.

HemosIL INR Validate (Levels 1-3)  

<table><tr><td rowspan=1 colspan=1>Reagent</td><td rowspan=1 colspan=1>Instrument</td><td rowspan=1 colspan=1>Level</td><td rowspan=1 colspan=1>Mean(Seconds)</td><td rowspan=1 colspan=1>Within-Run% CV</td><td rowspan=1 colspan=1>Total % CV</td></tr><tr><td rowspan=6 colspan=1>HemosILRecombiPlasTin</td><td rowspan=1 colspan=1>ACL TOP</td><td rowspan=2 colspan=1>1</td><td rowspan=1 colspan=1>28.1</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>1.5</td></tr><tr><td rowspan=1 colspan=1>ACL 10000</td><td rowspan=1 colspan=1>27.2</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>2.1</td></tr><tr><td rowspan=1 colspan=1>ACL TOP</td><td rowspan=2 colspan=1>2</td><td rowspan=1 colspan=1>43.5</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>2.5</td></tr><tr><td rowspan=1 colspan=1>ACL 10000</td><td rowspan=1 colspan=1>41.4</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>3.1</td></tr><tr><td rowspan=1 colspan=1>ACL TOP</td><td rowspan=2 colspan=1>3</td><td rowspan=1 colspan=1>68.3</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>3.5</td></tr><tr><td rowspan=1 colspan=1>ACL10000</td><td rowspan=1 colspan=1>65.5</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>1.5</td></tr><tr><td rowspan=6 colspan=1>HemosILRecombiPlasTin2G</td><td rowspan=1 colspan=1>ACLTOP</td><td rowspan=2 colspan=1>1</td><td rowspan=1 colspan=1>22.3</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>2.5</td></tr><tr><td rowspan=1 colspan=1>ACL10000</td><td rowspan=1 colspan=1>21.2</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.9</td></tr><tr><td rowspan=1 colspan=1>ACLTOP</td><td rowspan=2 colspan=1>2</td><td rowspan=1 colspan=1>33.9</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.8</td></tr><tr><td rowspan=1 colspan=1>ACL10000</td><td rowspan=1 colspan=1>32.0</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>3.0</td></tr><tr><td rowspan=1 colspan=1>ACLTOP</td><td rowspan=2 colspan=1>3</td><td rowspan=1 colspan=1>53.2</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>4.4</td></tr><tr><td rowspan=1 colspan=1>ACL10000</td><td rowspan=1 colspan=1>51.4</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>2.0</td></tr><tr><td rowspan=6 colspan=1>HemosIL PT-Fibrinogen HSPLUS</td><td rowspan=1 colspan=1>ACLTOP</td><td rowspan=2 colspan=1>1</td><td rowspan=1 colspan=1>24.7</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>2.5</td></tr><tr><td rowspan=1 colspan=1>ACL10000</td><td rowspan=1 colspan=1>24.5</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>1.7</td></tr><tr><td rowspan=1 colspan=1>ACLTOP</td><td rowspan=2 colspan=1>2</td><td rowspan=1 colspan=1>35.4</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>2.7</td></tr><tr><td rowspan=1 colspan=1>ACL10000</td><td rowspan=1 colspan=1>34.6</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>2.2</td></tr><tr><td rowspan=1 colspan=1>ACL TOP</td><td rowspan=2 colspan=1>3</td><td rowspan=1 colspan=1>50.5</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>4.2</td></tr><tr><td rowspan=1 colspan=1>ACL 10000</td><td rowspan=1 colspan=1>48.0</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>3.4</td></tr><tr><td rowspan=3 colspan=1>HemosIL PT-Fibrinogen HS*</td><td rowspan=1 colspan=1>ACL10000</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>21.2</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.9</td></tr><tr><td rowspan=1 colspan=1>ACL10000</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>32.0</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>3.0</td></tr><tr><td rowspan=1 colspan=1>ACL10000</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>51.4</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>2.0</td></tr><tr><td rowspan=6 colspan=1>HemosIL PT-Fibrinogen</td><td rowspan=1 colspan=1>ACLTOP</td><td rowspan=2 colspan=1>1</td><td rowspan=1 colspan=1>16.6</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>2.1</td></tr><tr><td rowspan=1 colspan=1>ACL10000</td><td rowspan=1 colspan=1>17.5</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>2.2</td></tr><tr><td rowspan=1 colspan=1>ACLTOP</td><td rowspan=2 colspan=1>2</td><td rowspan=1 colspan=1>21.0</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>3.4</td></tr><tr><td rowspan=1 colspan=1>ACL10000</td><td rowspan=1 colspan=1>22.4</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>3.6</td></tr><tr><td rowspan=1 colspan=1>ACLTOP</td><td rowspan=2 colspan=1>3</td><td rowspan=1 colspan=1>27.5</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>3.9</td></tr><tr><td rowspan=1 colspan=1>ACL 10000</td><td rowspan=1 colspan=1>29.8</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>4.1</td></tr></table>

\*Application is not currently available for HemosIL PT-Fibrinogen HS on the ACL TOP family.

# HemosIL ISI Calibrate (Levels A-D)

<table><tr><td colspan="1" rowspan="1">Reagent</td><td colspan="1" rowspan="1">Instrument</td><td colspan="1" rowspan="1">Level</td><td colspan="1" rowspan="1">Mean(Seconds)</td><td colspan="1" rowspan="1">Within-Run% CV</td><td colspan="1" rowspan="1">Total % CV</td></tr><tr><td colspan="1" rowspan="3">HemosILRecombiPlasTin</td><td colspan="1" rowspan="1">ACL TOP</td><td colspan="1" rowspan="2">A</td><td colspan="1" rowspan="1">12.1</td><td colspan="1" rowspan="1">1.2</td><td colspan="1" rowspan="1">1.3</td></tr><tr><td colspan="1" rowspan="1">ACL 10000</td><td colspan="1" rowspan="1">11.8</td><td colspan="1" rowspan="1">0.6</td><td colspan="1" rowspan="1">1.1</td></tr><tr><td colspan="1" rowspan="1">ACL TOP</td><td colspan="1" rowspan="1">B</td><td colspan="1" rowspan="1">29.5</td><td colspan="1" rowspan="1">0.8</td><td colspan="1" rowspan="1">1.2</td></tr><tr><td colspan="1" rowspan="5"></td><td colspan="1" rowspan="1">ACL 10000</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">27.9</td><td colspan="1" rowspan="1">1.3</td><td colspan="1" rowspan="1">2.0</td></tr><tr><td colspan="1" rowspan="1">ACL TOP</td><td colspan="1" rowspan="2">C</td><td colspan="1" rowspan="1">43.7</td><td colspan="1" rowspan="1">0.7</td><td colspan="1" rowspan="1">1.2</td></tr><tr><td colspan="1" rowspan="1">ACL 10000</td><td colspan="1" rowspan="1">42.2</td><td colspan="1" rowspan="1">0.7</td><td colspan="1" rowspan="1">1.1</td></tr><tr><td colspan="1" rowspan="1">ACL TOP</td><td colspan="1" rowspan="2">D</td><td colspan="1" rowspan="1">68.8</td><td colspan="1" rowspan="1">4.4</td><td colspan="1" rowspan="1">4.6</td></tr><tr><td colspan="1" rowspan="1">ACL 10000</td><td colspan="1" rowspan="1">66.9</td><td colspan="1" rowspan="1">0.8</td><td colspan="1" rowspan="1">2.0</td></tr><tr><td colspan="1" rowspan="8">HemosILRecombiPlasTin2G</td><td colspan="1" rowspan="1">ACL TOP</td><td colspan="1" rowspan="2">A</td><td colspan="1" rowspan="1">11.2</td><td colspan="1" rowspan="1">1.5</td><td colspan="1" rowspan="1">1.6</td></tr><tr><td colspan="1" rowspan="1">ACL 10000</td><td colspan="1" rowspan="1">10.7</td><td colspan="1" rowspan="1">0.8</td><td colspan="1" rowspan="1">1.2</td></tr><tr><td colspan="1" rowspan="1">ACL TOP</td><td colspan="1" rowspan="2">B</td><td colspan="1" rowspan="1">23.2</td><td colspan="1" rowspan="1">1.2</td><td colspan="1" rowspan="1">2.2</td></tr><tr><td colspan="1" rowspan="1">ACL10000</td><td colspan="1" rowspan="1">21.4</td><td colspan="1" rowspan="1">1.3</td><td colspan="1" rowspan="1">2.2</td></tr><tr><td colspan="1" rowspan="1">ACL TOP</td><td colspan="1" rowspan="2">C</td><td colspan="1" rowspan="1">33.9</td><td colspan="1" rowspan="1">1.0</td><td colspan="1" rowspan="1">1.7</td></tr><tr><td colspan="1" rowspan="1">ACL 10000</td><td colspan="1" rowspan="1">31.6</td><td colspan="1" rowspan="1">1.0</td><td colspan="1" rowspan="1">2.0</td></tr><tr><td colspan="1" rowspan="1">ACL TOP</td><td colspan="1" rowspan="2">D</td><td colspan="1" rowspan="1">50.8</td><td colspan="1" rowspan="1">4.4</td><td colspan="1" rowspan="1">4.9</td></tr><tr><td colspan="1" rowspan="1">ACL 10000</td><td colspan="1" rowspan="1">48.5</td><td colspan="1" rowspan="1">1.0</td><td colspan="1" rowspan="1">2.2</td></tr><tr><td colspan="1" rowspan="8">HemosIL PT-Fibrinogen HSPLUS</td><td colspan="1" rowspan="1">ACL TOP</td><td colspan="1" rowspan="2">A</td><td colspan="1" rowspan="1">13.4</td><td colspan="1" rowspan="1">1.0</td><td colspan="1" rowspan="1">2.1</td></tr><tr><td colspan="1" rowspan="1">ACL 10000</td><td colspan="1" rowspan="1">13.5</td><td colspan="1" rowspan="1">1.2</td><td colspan="1" rowspan="1">2.1</td></tr><tr><td colspan="1" rowspan="1">ACLTOP</td><td colspan="1" rowspan="2">B</td><td colspan="1" rowspan="1">24.0</td><td colspan="1" rowspan="1">1.8</td><td colspan="1" rowspan="1">2.5</td></tr><tr><td colspan="1" rowspan="1">ACL 10000</td><td colspan="1" rowspan="1">23.7</td><td colspan="1" rowspan="1">1.1</td><td colspan="1" rowspan="1">4.2</td></tr><tr><td colspan="1" rowspan="1">ACL TOP</td><td colspan="1" rowspan="2">C</td><td colspan="1" rowspan="1">35.1</td><td colspan="1" rowspan="1">1.2</td><td colspan="1" rowspan="1">2.2</td></tr><tr><td colspan="1" rowspan="1">ACL 10000</td><td colspan="1" rowspan="1">35.2</td><td colspan="1" rowspan="1">1.1</td><td colspan="1" rowspan="1">1.8</td></tr><tr><td colspan="1" rowspan="1">ACL TOP</td><td colspan="1" rowspan="2">D</td><td colspan="1" rowspan="1">50.4</td><td colspan="1" rowspan="1">3.4</td><td colspan="1" rowspan="1">3.9</td></tr><tr><td colspan="1" rowspan="1">ACL 10000</td><td colspan="1" rowspan="1">50.1</td><td colspan="1" rowspan="1">0.8</td><td colspan="1" rowspan="1">2.0</td></tr><tr><td colspan="1" rowspan="4">HemosIL PT-Fibrinogen HS*</td><td colspan="1" rowspan="1">ACL 10000</td><td colspan="1" rowspan="1">A</td><td colspan="1" rowspan="1">10.7</td><td colspan="1" rowspan="1">0.1</td><td colspan="1" rowspan="1">1.2</td></tr><tr><td colspan="1" rowspan="1">ACL10000</td><td colspan="1" rowspan="1">B</td><td colspan="1" rowspan="1">21.4</td><td colspan="1" rowspan="1">1.3</td><td colspan="1" rowspan="1">2.2</td></tr><tr><td colspan="1" rowspan="1">ACL 10000</td><td colspan="1" rowspan="1">C</td><td colspan="1" rowspan="1">31.6</td><td colspan="1" rowspan="1">1.0</td><td colspan="1" rowspan="1">2.0</td></tr><tr><td colspan="1" rowspan="1">ACL 10000</td><td colspan="1" rowspan="1">D</td><td colspan="1" rowspan="1">48.5</td><td colspan="1" rowspan="1">1.0</td><td colspan="1" rowspan="1">2.2</td></tr><tr><td colspan="1" rowspan="8">HemosIL PT-Fibrinogen</td><td colspan="1" rowspan="1">ACL TOP</td><td colspan="1" rowspan="2">A</td><td colspan="1" rowspan="1">11.7</td><td colspan="1" rowspan="1">0.9</td><td colspan="1" rowspan="1">1.8</td></tr><tr><td colspan="1" rowspan="1">ACL 10000</td><td colspan="1" rowspan="1">11.9</td><td colspan="1" rowspan="1">0.8</td><td colspan="1" rowspan="1">1.4</td></tr><tr><td colspan="1" rowspan="1">ACL TOP</td><td colspan="1" rowspan="2">B</td><td colspan="1" rowspan="1">16.0</td><td colspan="1" rowspan="1">0.4</td><td colspan="1" rowspan="1">2.3</td></tr><tr><td colspan="1" rowspan="1">ACL 10000</td><td colspan="1" rowspan="1">16.8</td><td colspan="1" rowspan="1">0.7</td><td colspan="1" rowspan="1">2.3</td></tr><tr><td colspan="1" rowspan="1">ACL TOP</td><td colspan="1" rowspan="2">C</td><td colspan="1" rowspan="1">20.7</td><td colspan="1" rowspan="1">0.3</td><td colspan="1" rowspan="1">2.9</td></tr><tr><td colspan="1" rowspan="1">ACL 10000</td><td colspan="1" rowspan="1">22.2</td><td colspan="1" rowspan="1">0.9</td><td colspan="1" rowspan="1">3.0</td></tr><tr><td colspan="1" rowspan="1">ACL TOP</td><td colspan="1" rowspan="2">D</td><td colspan="1" rowspan="1">26.6</td><td colspan="1" rowspan="1">0.4</td><td colspan="1" rowspan="1">3.7</td></tr><tr><td colspan="1" rowspan="1">ACL 10000</td><td colspan="1" rowspan="1">28.8</td><td colspan="1" rowspan="1">0.4</td><td colspan="1" rowspan="1">3.5</td></tr></table>

\*Application is not currently available for HemosIL PT-Fibrinogen HS on the ACL TOP family.

An additional precision study was performed utilizing CLSI H54-A on three lots. Two replicates per run over 3 days $( \mathrm { n } { = } 6 )$ for each level of control and calibrator using the following reagent and instruments:

HemosIL PT-Fibrinogen, HemosIL PT-Fibrinogen HS (not available on the

ACL TOP family), HemosIL PT-Fibrinogen HS PLUS, HemosILRecombiPlasTin 2G, and HemosIL RecombiPlasTin.

ACL300, ACL 3000, ACL 6000, ACL 10000, ACL Advance, and ACL TOP. For the HemosIL Validate, levels 1-3 met their within-run $\%$ CV specification of $\leq 6 \%$ . For the HemosIL Calibrate, Level A and Levels B-D met their within-run $\%$ CV specification of $\leq 3 \%$ and $6 \%$ , respectively.

b. Linearity/assay reportable range: Not applicable   
c. Traceability, Stability, Expected values (controls, calibrators, or methods): Traceability: The traceability of the tri-level HemosIL Validate and the fourlevel HemosIL Calibrate with INR reference values are summarized as follows: The House Standard ISI Calibrate INR reference value is derived from the mean INR reference values from combined sources of ${ > } 2 0 0$ laboratories and three WHO laboratories. At the WHO laboratories, Human IRP (RTF/95) and Rabbit IRP (RBT/05) were used. The House Standard ISI/MNPT for each instrument/reagent combination are derived from House Standard Calibration curves using the House Standard ISI Calibrate reference INR values and PT (seconds). Reagent-specific INR reference values for each production lot of HemosIL Calibrate and HemosIL Validate are calculated from the mean PT (seconds) and the House Standard ISI/MNPT on the same instrument/reagent combinations as the assignment of the House Standard ISI and MNPT.

# Stability:

Reconstituted stability studies were performed to support the reconstituted stability for the HemosIL Validate and HemosIL Calibrate. Two lots were used in the studies for each device. At different time intervals, the stored control and calibrator levels were analyzed in a minimum of four replicates and the mean results were compared to the Time 0 mean results.

8 hours at $2 { - } 8 ^ { \circ } \mathrm { C }$ in the original vial   
30 days at $\mathrm { - 2 0 ^ { \circ } C }$ in the original vial   
4 hours at $1 5 { - } 2 5 ^ { \circ } \mathrm { C }$ on-board IL Coagulation System

A shelf life stability study is ongoing at $2 { - } 8 ^ { \circ } \mathrm { C }$ using three different lots of HemosIL Validate and HemosIL Calibrate plasmas. At different time intervals, the plasmas were run in a minimum of four replicates using the representative $\mathrm { I L }$ instrument/PT reagent combinations. The results were compared to the Time 0 mean results. The package insert instructs the end user to use the expiration date as shown on the vial. The results to date are within acceptable limits of $\pm 1 0 \%$ difference from Time 0 mean results.

d. Detection limit: Not applicable e. Analytical specificity: Not applicable

f. Assay cut-off: Not applicable

2. Comparison studies: a. Method comparison with predicate device:

Not applicable b. Matrix comparison: Not applicable

3. Clinical studies:

a. Clinical Sensitivity: Not applicable   
b. Clinical specificity: Not applicable   
c. Other clinical supportive data (when a. and b. are not applicable): An external testing was performed to evaluate the performance of the HemosIL Validate and HemosIL Calibrate. Specific instrument/PT reagent combination was used in the study. Data indicate that the INR Validate and ISI Calibrate met performance specification: the mean INR was within $\pm 1 5 \%$ of the reference value for each level of the plasma controls.

4. Clinical cut-off: Not applicable

5. Expected values/Reference range: Not applicable

. Proposed Labeling: The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.